Long-term outcomes of patients with chronic inflammatory diseases after percutaneous coronary intervention.
acute coronary syndrome
inflammatory rheumatic diseases
mortality
outcomes
percutaneous coronary intervention
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
revised:
19
06
2021
received:
02
04
2021
accepted:
02
07
2021
pubmed:
15
7
2021
medline:
15
12
2021
entrez:
14
7
2021
Statut:
ppublish
Résumé
To assess the long-term outcomes of patients with chronic inflammatory diseases who underwent percutaneous coronary intervention (PCI). A Retrospective cohort study of all adult patients who underwent PCI in a large tertiary care center from January 2002 to August 2020. A total of 12,951 patients underwent PCI during the study period and were included in the cohort. The population of chronic inflammatory diseases includes 247 (1.9%) patients; 70 with inflammatory bowel disease (IBD) and 173 with autoimmune rheumatic diseases (AIRD). The composite endpoint of mortality, acute coronary syndrome (ACS) or admission due to acute heart failure was similar at 30 days and more frequent in the inflammatory disease group (42.8% in AIRD group, 35.7% in the IBD group and 29.6% in the noninflammatory group, p < 0.0001). The adjusted cox regression model found a statistically significant increased risk of the composite primary endpoints of around 40% for patients both with AIRD and IBD. Readmission due to ACS was also increases at 30 days in the AIRD group compared to the noninflammatory group (0.6% vs. 0.1%, p < 0.001) and 1 year (37.6% for the AIRD group, 34.3% in the IBD group and 25.5% in the noninflammatory group (p < 0.0001). Patients with inflammatory diseases were found to have a significantly increased risk congestive heart failure admissions at 1 year in a subgroup analysis of patients with myocardial infarction. Patients with AIRD and IBD are at higher risk for cardiovascular events in long-term follow up once diagnosed with CAD and treated with PCI.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E655-E660Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11:229.
Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71:1524-1525.
Aniwan S, Pardi DS, Tremaine WJ, Loftus EV. Increased risk of acute myocardial infarction and heart failure in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16:1607-1615.e1.
Choi YJ, Lee DH, Shin DW, et al. Patients with inflammatory bowel disease have an increased risk of myocardial infarction: a nationwide study. Aliment Pharmacol Ther. 2019;50:769-779.
Feng W, Chen G, Cai D, Zhao S, Cheng J, Shen H. Inflammatory bowel disease and risk of ischemic heart disease: an updated meta analysis of cohort studies. J Am Heart Assoc. 2017;6:e005892.
Martinez SC, Mohamed M, Potts J, et al. Percutaneous coronary intervention outcomes in patients with rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. Rheumatology. 2020;59:2512-2522.
Mantel A, Holmqvist M, Jernberg T, Wallberg-Jonsson S, Askling J. Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome. Eur Heart J. 2015;36:3413-3422.
Lai CH, Lai WW, Chiou MJ, et al. Outcomes of percutaneous coronary intervention in patients with rheumatoid arthritis and systemic lupus erythematosus: an 11-year nationwide cohort study. Ann Rheum Dis. 2016;75:1350-1356.
Maksimowicz-McKinnon K, Selzer F, Manzi S, et al. Poor 1-year outcomes after percutaneous coronary interventions in systemic lupus erythematosus: report from the National Heart, Lung, and Blood Institute dynamic registry. Circ Cardiovasc Interv. 2008;1:201-208.
Kobo O, Mohamed MO, Farmer AD, et al. Outcomes of percutaneous coronary intervention in patients with Crohn's disease and ulcerative colitis (from a Nationwide cohort). Am J Cardiol. 2020;130:30-36.
Aggarwal A, Atreja A, Kapadia S, Lopez R, Achkar JP. Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease. Inflamm Bowel Dis. 2014;20:1593-1601.
Sintek MA, Sparrow CT, Mikuls TR, et al. Repeat revascularisation outcomes after percutaneous coronary intervention in patients with rheumatoid arthritis. Heart. 2016;102:363-369.
Nochioka K, Biering-Sørensen T, Hansen KW, et al. Long-term outcomes in patients with rheumatologic disorders undergoing percutaneous coronary intervention: a BAsel stent Kosten-Effektivitäts ts TrialPROspective validation examination (BASKET-PROVE) sub-study. Eur Heart J Acute Cardiovasc Care. 2017;6:778-786.
Spartera M, Godino C, Baldissera E, et al. Long-term clinical outcomes of patients with rheumatoid arthritis and concomitant coronary artery disease. Am J Cardiovasc Dis. 2017;7:9-18.
Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52:412-420.
Agarwal M, Agrawal S, Garg L, et al. National trends in the incidence, management, and outcomes of heart failure complications in patients hospitalized for ST-segment elevation myocardial infarction. Mayo Clin Proc Innov Qual Outcomes. 2017;1:26-36.
Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Eur Heart J. 2018;39:3499-3507.
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497-2505.
Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838-1847.
Hafström I, Rohani M, Deneberg S, Wörnert M, Jogestrand T, Frostegård J. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis-a randomized study. J Rheumatol. 2007;34:1810-1816.
Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380:752-762.
O'Donoghue ML, Glaser R, Cavender MA, et al. Effect of Losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA. 2016;315:1591-1599.
Ahlers MJ, Lowery BD, Farber-Eger E, et al. Heart failure risk associated with rheumatoid arthritis-related chronic inflammation. J Am Heart Assoc. 2020;9:e01466.